[1]高琪,周欢娣,韩雪涛,等.甲状腺相关眼病预后因素及治疗的研究进展[J].眼科新进展,2021,41(7):696-700.[doi:10.13389/j.cnki.rao.2021.0145]
　GAO Qi,ZHOU Huandi,HAN Xuetao,et al.Current progress of prognostic factors and treatment for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2021,41(7):696-700.[doi:10.13389/j.cnki.rao.2021.0145]
点击复制

甲状腺相关眼病预后因素及治疗的研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年7期
页码:
696-700
栏目:
文献综述
出版日期:
2021-07-05

文章信息/Info

Title:
Current progress of prognostic factors and treatment for thyroid-associated ophthalmopathy
作者:
高琪; 周欢娣; 韩雪涛; 薛晓英
050000　河北省石家庄市，河北医科大学第二医院
Author(s):
GAO Qi; ZHOU Huandi; HAN Xuetao; XUE Xiaoying
The Second Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China
关键词:
甲状腺相关眼病; 预后因素; 发病机制; 放疗
Keywords:
thyroid-associated ophthalmopathy; prognostic factors; pathogenesis; radiotherapy
分类号:
R777.5
DOI:
10.13389/j.cnki.rao.2021.0145
文献标志码:
A
摘要:
甲状腺相关眼病（TAO），又称Graves眼病，是Graves病最常见、最复杂的甲状腺以外受累的器官病变，影响其发生发展的因素很多，遗传、环境等因素均影响患者预后。目前其发病机制尚不明确，也无针对病因的有效治疗方法，临床常用的有药物治疗、球后放疗、手术治疗等多种治疗方式。近年来免疫治疗取得重大进展，为TAO的治疗提供了新的选择。现就TAO治疗及预后因素的最新进展作一综述。
Abstract:
Thyroid-associated ophthalmopathy (TAO), also known as Graves ophthalmopathy, is the most common and complex organ lesion of Graves disease with non-thyroid involvement. There are many factors affecting its occurrence and development, including genetic and environmental factors, which affect the prognosis of patients. At present, the pathogenesis of the disease is not clear, and there is no effective therapy for the cause of the disease. The commonly used clinical treatment methods include drug therapy, orbital radiotherapy, surgical treatment and so on. With the great progress of immunotherapy in recent years, it provides a new option for TAO treatment. We will give a review on the prognostic factors and the latest progress in the treatment of TAO in this article.

参考文献/References:

［1］　TANDA M L,PIANTANIDA E,LIPARULO L,VERONESI G,LAI A,SASSI L,et al.Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center［J］.J Clin Endocrinol Metab,2013,98(4):1443-1449.
［2］　ZHANG L,GRENNAN-JONES F,DRAMAN M S,LANE C,MORRIS D,DAYAN C M,et al.Possible targets for nonimmunosuppressive therapy of Graves’ orbitopathy［J］.J Clin Endocrinol Metab,2014,99(7):E1183-1190.
［3］　SMITH T J,HEGEDS L,DOUGLAS R S.Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy［J］.Best Pract Res Clin Endocrinol Metab,2012,26(3):291-302.
［4］　CHEN H,SHAN S J,MESTER T,WEI Y H,DOUGLAS R S.TSH-mediated TNFα production in human fibrocytes is inhibited by teprotumumab,an IGF-1R antagonist［J］.PLoS One,2015,10(6):e0130322.
［5］　MARKHAM A.Teprotumumab:first approval［J］.Drugs,2020,80(5):509-512.
［6］　PRABHAKAR B S,BAHN R S,SMITH T J.Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy［J］.Endocr Rev,2003,24(6):802-835.
［7］　HASHAM A,TOMER Y.Genetic and epigenetic mechanisms in thyroid autoimmunity［J］.Immunol Res,2012,54(1/3):204-213.
［8］　WU T,TANG D R,ZHAO L,SUN F Y.Poly (ADP-ribose) polymerase-1 (PARP-1) in Chinese patients with Graves’ disease and Graves’ ophthalmopathy［J］.Can J Physiol Pharmacol,2018,96(6):556-561.
［9］　ZHANG M,LIU S,XU J,L S,FAN Y,ZHANG Y,et al.TNFSF15 polymorphisms are associated with Graves’ disease and Graves’ ophthalmopathy in a Han Chinese population［J］.Curr Eye Res,2020,45(7):888-895.
［10］　XIONG H,WU M,YI H,WANG X,WANG Q,NADIRSHINA S,et al.Genetic associations of the thyroid stimulating hormone receptor gene with Graves diseases and Graves ophthalmopathy:a meta-analysis［J］.Sci Rep,2016,6:30356.
［11］　GONG J,JIANG S J,WANG D K,DONG H,CHEN G,FANG K,et al.Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves’ disease:a meta-analysis［J］.J Huazhong Univ Sci Technol Med Sci,2016,36(4):473-479.
［12］　PLAZINSKA M T,SAWICKA-GUTAJ N,CZARNYWOJTEK A,WOLINSKI K,KOBYLECKA M,KARLI N ＇ SKA M,et al.Radioiodine therapy and Graves’ disease:myths and reality［J］.PLoS One,2020,15(1):e0226495.
［13］　CZARNYWOJTEK A,KOMAR-RYCHLICKA K,ZGORZALEWICZ-STACHOWIAK M,SAWICKA-GUTAJ N,WOLIńSKI K,GUT P,et al.Efficacy and safety of radioiodine therapy for mild Graves ophthalmopathy depending on cigarette consumption:a 6-month follow-up［J］.Pol Arch Med Wewn,2016,126(10):746-753.
［14］　WIERSINGA W M.Smoking and thyroid［J］.Clin Endocrinol (Oxf),2013,79(2):145-151.
［15］　XING L,YE L,ZHU W,SHEN L,HUANG F,JIAO Q,et al.Smoking was associated with poor response to intravenous steroids therapy in Graves’ ophthalmopathy［J］.Br J Ophthalmol,2015,99(12):1686-1691.
［16］　GRTZ G E,HORSTMANN M,ANIOL B,REYES B D,FANDREY J,ECKSTEIN A,et al.Hypoxia-dependent HIF-1 activation impacts on tissue remodeling in Graves’ ophthalmopathy-implications for smoking［J］.J Clin Endocrinol Metab,2016,101(12):4834-4842.
［17］　CHNG C L,LAI O F,CHEW C S,PEH Y P,FOOK-CHONG S M,SEAH L L,et al.Hypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts-a possible explanation of the link between smoking and Graves’ ophthalmopathy［J］.Int J Ophthalmol,2014,7(3):403-407.
［18］　PLANCK T,SHAHIDA B,PARIKH H,STRM K,SMAN P,BRORSON H,et al.Smoking induces overexpression of immediate early genes in active Graves’ ophthalmopathy［J］.Thyroid,2014,24(10):1524-1532.
［19］　BADYS-WALIGRSKA A,GOKOWSKI F,KUSNIERZ-CABALA B,BUZIAK-BEREZA M,HUBALEWSKA-DYDEJCZYK A.Graves’ ophthalmopathy in patients treated with radioiodine 131-I［J］.Endokrynol Pol,2011,62(3):214-219.
［20］　PONTO K A,ZANG S,KAHALY G J.The tale of radioiodine and Graves’ orbitopathy［J］.Thyroid,2010,20(7):785-793.
［21］　KHIYANI N,DADPARVAR S,GISH A,INTENZO C M,MALMUD L S.Does the dose of iodine-131 influence the incidence of Graves’ ophthalmopathy?［J］.Nucl Med Commun,2019,40(5):455-460.
［22］　SHIBER S,STIEBEL-KALISH H,SHIMON I,GROSSMAN A,ROBENSHTOK E.Glucocorticoid regimens for prevention of Graves’ ophthalmopathy progression following radioiodine treatment:systematic review and meta-analysis［J］.Thyroid,2014,24(10):1515-1523.
［23］　LI H X,XIANG N,HU W K,JIAO X L.Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy:a systematic review and meta-analysis［J］.J Endocrinol Invest,2016,39(11):1225-1233.
［24］　ROY A,DUTTA D,GHOSH S,MUKHOPADHYAY P,MUKHOPADHYAY S,CHOWDHURY S.Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves’ orbitopathy:a randomized controlled trial［J］.Indian J Endocrinol Metab,2015,19(3):351-358.
［25］　GAO G,DAI J,QIAN Y,MA F.Meta-analysis of methylprednisolone pulse therapy for Graves’ ophthalmopathy［J］.Clin Exp Ophthalmol,2014,42(8):769-777.
［26］　ZHAO L Q,YU D Y,CHENG J W.Intravenous glucocorticoids therapy in the treatment of Graves’ ophthalmopathy:a systematic review and meta-analysis［J］.Int J Ophthalmol,2019,12(7):1177-1186.
［27］　LIU X,WANG S,QIN L,QIANG W,DAHAL M,FAN P,et al.Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy［J］.Exp Ther Med,2016,12(2):901-908.
［28］　BARTALENA L,KRASSAS G E,WIERSINGA W,MARCOCCI C,SALVI M,DAUMERIE C,et al.Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy［J］.J Clin Endocrinol Metab,2012,97(12):4454-4463.
［29］　BARTALENA L,BALDESCHI L,BOBORIDIS K,ECKSTEIN A,KAHALY G J,MARCOCCI C,et al.The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy［J］.Eur Thyroid J,2016,5(1):9-26.
［30］　SALVI M,VANNUCCHI G,CURR N,CAMPI I,COVELLI D,DAZZI D,et al.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy:a randomized controlled study［J］.J Clin Endocrinol Metab,2015,100(2):422-431.
［31］　STAN M N,GARRITY J A,CARRANZA LEON B G,PRABIN T,BRADLEY E A,BAHN R S.Randomized controlled trial of rituximab in patients with Graves’ orbitopathy［J］.J Clin Endocrinol Metab,2015,100(2):432-441.
［32］　EID L,COSTE-VERDIER V,LONGUEVILLE E,RIBEIRO E,NICOLESCU-CATARGI B,KOROBELNIK J F.The effects of Rituximab on Graves’orbitopathy:a retrospective study of 14 patients［J］.Eur J Ophthalmol,2020,30(5):1008-1013.
［33］　GRASSI P,STRIANESE D,PISCOPO R,PACELLI R,BONAVOLONT G.Radiotherapy for the treatment of thyroid eye disease-a prospective comparison:is orbital radiotherapy a suitable alternative to steroids?［J］.Ir J Med Sci,2017,186(3):647-652.
［34］　KIM J W,HAN S H,SON B J,RIM T H,KEUM K C,YOON J S.Efficacy of combined orbital radiation and systemic steroids in the management of Graves’ orbitopathy［J］.Graefes Arch Clin Exp Ophthalmol,2016,254(5):991-998.
［35］　SISTI E,MENCONI F,LEO M,PROFILO M A,MAUTONE T,MAZZI B,et al.Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy［J］.J Endocrinol Invest,2015,38(6):661-668.
［36］　OEVERHAUS M,WITTELER T,LAX H,ESSER J,FHRER D,ECKSTEIN A.Combination therapy of intravenous steroids and orbital irradiation is more effective than intravenous steroids alone in patients with Graves’ orbitopathy［J］.Horm Metab Res,2017,49(10):739-747.
［37］　GOLD K G,SCOFIELD S,ISAACSON S R,STEWART M W,KAZIM M.Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy［J］.Ophthalmic Plast Reconstr Surg,2018,34(2):172-177.
［38］　RAJENDRAM R,TAYLOR P N,WILSON V J,HARRIS N,MORRIS O C,TOMLINSON M,et al.Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED):a multicentre,2×2 factorial,double-blind,randomised controlled trial［J］.Lancet Diabetes Endocrinol,2018,6(4):299-309.
［39］　OHTSUKA K,SATO A,KAWAGUCHI S,HASHIMOTO M,SUZUKI Y.Effect of steroid pulse therapy with and without orbital radiotherapy on Graves’ ophthalmopathy［J］.Am J Ophthalmol,2003,135(3):285-290.
［40］　NG C M,YUEN H K,CHOI K L,CHAN M K,YUEN K T,NG Y W,et al.Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves’ ophthalmopathy:a preliminary study［J］.Hong Kong Med J,2005,11(5):322-330.
［41］　BARTALENA L,MARCOCCI C,TANDA M L,PIANTANIDA E,LAI A,MARIN M,et al.An update on medical management of Graves’ ophthalmopathy［J］.J Endocrinol Invest,2005,28(5):469-478.
［42］　ARENAS M,GIL F,GIRONELLA M,HERNNDEZ V,JORCANO S,BIETE A,et al.Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice［J］.Int J Radiat Oncol Biol Phys,2006,66(2):560-567.
［43］　ARENAS M,GIL F,GIRONELLA M,HERNNDEZ V,BIETE A,PIQU E ＇ J M,et al.Time course of anti-inflammatory effect of low-dose radiotherapy:correlation with TGF-beta1 expression［J］.Radiother Oncol,2008,86(3):399-406.
［44］　CARDOSO C C,GIORDANI A J,WOLOSKER A M,SOUHAMI L,MANSO P G,DIAS R S,et al.Protracted hypofractionated radiotherapy for Graves’ ophthalmopathy:a pilot study of clinical and radiologic response［J］.Int J Radiat Oncol Biol Phys,2012,82(3):1285-1291.
［45］　GULER O C,ONAL C,ARSLAN G.Graves’ ophthalmopathy treated with protracted hypofractionated low-dose adaptive radiotherapy:case report and review of the literature［J］.Wien Klin Wochenschr,2016,128(7/8):299-303.
［46］　JEFFERIS J M,JONES R K,CURRIE Z I,TAN J H,SALVI S M.Orbital decompression for thyroid eye disease:methods,outcomes,and complications［J］.Eye (Lond),2018,32(3):626-636.
［47］　WOODS R,PILSON Q,KHARYTANIUK N,CASSIDY L,KHAN R,TIMON C.Outcomes of endoscopic orbital decompression for graves’ ophthalmopathy［J］.Ir J Med Sci,2020,189(1):177-183.
［48］　PREVOST A,DEKEISTER C,CARON P,IMBERT P,CAVALLIER Z,LAUWERS F,et al.Outcomes of orbital decompression using surgical navigation in thyroid-associated ophthalmopathy［J］.Int J Oral Maxillofac Surg,2020,49(10):1279-1285.
［49］　CHU E A,MILLER N R,LANE A P.Selective endoscopic decompression of the orbital apex for dysthyroid optic neuropathy［J］.Laryngoscope,2009,119(6):1236-1240.

相似文献/References:

[1]杨文娟 班胜刚 何剑峰.甲状腺相关眼病患者外周血单个核细胞中微小 RNA-146a的异常表达及意义[J].眼科新进展,2012,32(5):000.
[2]王方 朱豫 栗夏莲 明亮.甲状腺相关眼病患者血清中白细胞介素-15和白细胞介素-21的含量及临床意义[J].眼科新进展,2013,33(6):000.
[3]刘芳 朱豫 韩宝红.血清 sICAM-1及透明质酸与糖皮质激素治疗TAO敏感性关系的研究[J].眼科新进展,2012,32(2):000.
[4]刘振华 朱豫.甲状腺相关眼病患者血清可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1的检测及临床意义[J].眼科新进展,2013,33(4):000.
[5]唐建,罗清礼. 瘦素基因在甲状腺相关眼病眶脂肪及体外分化眶脂肪细胞中的表达[J].眼科新进展,2014,34(9):801.[doi:10.13389/j.cnki.rao.2014.0222]
[6]金珂,朱豫. 甲状腺相关眼病患者干眼症患病率及特征分析[J].眼科新进展,2015,35(5):473.[doi:10.13389/j.cnki.rao.2015.0129]
　JIN Ke,ZHU Yu. Analysis of prevalence and characteristic of dry eye in patients with thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2015,35(7):473.[doi:10.13389/j.cnki.rao.2015.0129]
[7]欧阳明,刘桂琴,樊宁,等.小蘖碱对甲状腺相关眼病眼眶前脂肪细胞分化的影响[J].眼科新进展,2016,36(1):012.[doi:10.13389/j.cnki.rao.2016.0004]
　OU-YANG Ming,LIU Gui-Qin,FAN Ning,et al.Effects of berberine on differerntiation of orbital preadipocytes of TAO patients in vitro[J].Recent Advances in Ophthalmology,2016,36(7):012.[doi:10.13389/j.cnki.rao.2016.0004]
[8]何小寒,刘桂琴,蒋丽琼,等.甲状腺相关眼病患者和正常人眼眶脂肪组织中脂肪特异性磷脂酶A2的表达[J].眼科新进展,2016,36(9):841.[doi:10.13389/j.cnki.rao.2016.0225]
　HE Xiao-Han,LIU Gui-Qin,JIANG Li-Qiong,et al.Expression of AdPLA in orbital adipose tissue of normal and patients with thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2016,36(7):841.[doi:10.13389/j.cnki.rao.2016.0225]
[9]刘桂琴,欧阳明,王云,等.AdPLA 基因在Ⅲ级静止期甲状腺相关眼病眼眶脂肪内高表达研究[J].眼科新进展,2017,37(4):354.[doi:10.13389/j.cnki.rao.2017.0090]
　LIU Gui-Qin,OU-YANG Ming,WANG Yun,et al.Higher expression of AdPLA in orbital adipose tissue of patients with thyroid associated ophthalmopathy of Ⅲ level and stationary phase[J].Recent Advances in Ophthalmology,2017,37(7):354.[doi:10.13389/j.cnki.rao.2017.0090]
[10]严劼,李妍,胡竹林.不同治疗方法对改善甲状腺相关眼病症状的效果评价[J].眼科新进展,2019,39(8):758.[doi:10.13389/j.cnki.rao.2019.0173]
　YAN Jie,LI Yan,HU Zhu-Lin.The observation of different treatments for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2019,39(7):758.[doi:10.13389/j.cnki.rao.2019.0173]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2021-07-05